Clinical impact of 18F-FDG PET/CT in the pretreatment evaluation of patients with locally advanced cervical carcinoma

Aim The aim of this study was to evaluate the impact of F-18-fluorodeoxyglucose (F-18-FDG) PET/computed tomography (CT) on the pretreatment evaluation of patients with locally advanced cervical carcinoma. Method Forty-seven patients with stage 2b-4a cervical carcinoma underwent F-18-FDG PET/CT for initial staging and pretreatment evaluation. Concomitant pelvic/abdominal MRI was performed in 38 patients. The contribution of PET/CT to treatment planning was evaluated, and the prognostic performance of PET/CT was compared with that of MRI. Lymph node (LN) status on PET/CT was correlated with patient follow-up data. Results PET/CT detected hypermetabolic LNs in 39/47 patients. In 24/39 patients (62%), PET/CT was found to be superior to MRI. In 13/24 patients (54%), PET/CT detected para-aortic +/- pelvic LNs, which were not found on MRI. PET/CT successfully detected distant metastases in 10 patients and peritonitis carcinomatosa in one patient; these patients were upstaged clinically. Overall, PET/CT has led to modifications in the extent of the radiotherapy field in 34% of patients and to major alterations in treatment plans in 23% of patients with widespread disease. The frequency of PET-positive LNs was significantly lower in patients who were alive without disease at the time of last follow-up (60%) compared with patients with persistent disease and nonsurvivors (100%, P=0.012). Conclusion The presence of PET-positive LNs has prognostic significance in patients with cervical carcinoma. PET/CT has the potential to show both lymphatic and distant metastases, which results in modifications to the chemoradiotherapeutic regimen. The use of PET/CT must be included in the initial workup of patients with locally advanced cervical carcinoma. Nucl Med Commun 33:1081-1088 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.